Company intelligence / Profile preview

MicroOptx

Maple Grove, Minnesota, United States of Americaselling.com ↗

Ownership: Private
Employees: ~16
Development stage: Preclinical

Overview

MicroOptx has developed the Beacon Aqueous Microshunt, a minimally invasive implantable device designed to drain excess fluid from the anterior chamber of the eye to reduce intraocular pressure in glaucoma patients. The company completed initial patient enrollment for its U.S. pivotal clinical trial and is pursuing regulatory approvals in the U.S., Canada, and EU. Early results are focused on safety, performance, and effective IOP reduction. No commercial launch or published pivotal data as of June 2025.

Therapeutic areas: Ophthalmology
Modalities: DevicePlatform technology (medical device)
Industry: Implantable Medical Devices

Drug pipeline

1 asset

Beacon Aqueous Microshunt

Pre-clinical

Indications: Glaucoma

Beyond the preview

Go deeper on MicroOptx.

Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from trial design and recruitment through results.

Trial phase
Status
Readouts

Licensing & deals

Explore licensing agreements, acquisitions, and the assets behind each deal.

Partners
Deal terms
Milestones

Funding history

Trace financing activity and the investors behind a company’s development.

Funding rounds
Investors
Capital raised

Competitive landscape

Compare peer pipelines by target, modality, and therapeutic area.

Peer companies
Targets
Pipeline overlap

Technologies & patents

Explore technology platforms and the patent landscape around relevant assets.

Platforms
Patents
Assignees

Research & analysis

Connect company news and source material to the questions you’re investigating.

Company news
Sources
Analysis

Bring the full picture into focus.

See how Gosset can support your research on MicroOptx.

Explore the full profile